GYRE beat EPS expectations by 194.12%
Nov 07, 2025, 11:35 PM
0.00%
What does GYRE do
Gyre Therapeutics, a San Diego-based biopharmaceutical company with 593 employees, focuses on developing F351 for treating NASH-associated fibrosis and has a pipeline through its indirect interest in Gyre Pharmaceuticals. The company went public on April 12, 2006, and also offers the drug ETUARY.
Gyre Therapeutics (GYRE) reported a positive EPS surprise in its most recent quarterly earnings. For the most recent quarter, Gyre Therapeutics's actual EPS was $0.08, beating the estimate of $0.03 per share, resulting in a 194.12% surprise.
📡️ Health Care
Earnings Surprise
More Signals
Feature in Progress
This section is under development. Check back soon for updates!
Cashu is the #1 way to stay ahead of the markets, know why your favourite stocks are moving and access valuation signals that smash the market.